acf/google-ad-placement

The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Complete Genomics, Inc. <span class="ticker"
                data-ticker="GNOM"
                data-exchange="NASDAQ"
                style="display: inline-block;">GNOM</span> and Oncothyreon Inc. <span class="ticker"
                data-ticker="ONTY"
                data-exchange="NASDAQ"
                style="display: inline-block;">ONTY</span>. 

Access to the full company reports can be found at:
www.ParagonReport.com/GNOM
www.ParagonReport.com/ONTY 

Under the new pathway the FDA would allow developers of such drugs to conduct smaller, faster clinical trial, and provide a "special medical use" label which would allow doctors to administer drugs to patients with critical need. Hamburg has said that the FDA needs to take into account the needs people with deadly or debilitating diseases that may be willing to take on the risks of unproven drugs. 


News

FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases  - Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Application error: a client-side exception has occurred (see the browser console for more information).